Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Icilin is a synthetic small molecule that functions as a super-agonist of the transient receptor potential M8 (TRPM8) ion channel. It is known for producing an intense sensation of cold, being significantly more potent and efficacious than menthol. Beyond its primary action on TRPM8, icilin also acts as an inhibitor of the transient receptor potential V3 (TRPV3) channel and an agonist of the human epithelial Na+ channel (hENaC). Research indicates its potential involvement in various physiological processes and conditions, including migraine pathophysiology, autoimmune neuroinflammation, pruritus, colitis, and certain types of cancer, where it has shown effects such as attenuating inflammatory responses and inhibiting cancer cell motility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on icilin.